Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial

Drug and Alcohol Dependence

Volumn 99, Issue 1-3, 2009, Pages 222-230

  Magura, Stephen ^a,b   Lee, Joshua D ^c   Hershberger, Jason ^d   Joseph, Herman ^b   Marsch, Lisa ^b   Shropshire, Carol ^e   Rosenblum, Andrew ^b  

^a WESTERN MICHIGAN UNIVERSITY   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^c BELLEVUE HOSPITAL CENTER   (United States)

^d NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^e Prison Health Services Inc   (United States)

Author keywords

Buprenorphine treatment; Jail; Methadone treatment; Prisoners; Substance abuse treatment

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; HYDROCODONE; ILLICIT DRUG; METHADONE; OPIATE; OPIATE AGONIST; OXYCODONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRIME; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HEADACHE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; METHADONE TREATMENT; PRIORITY JOURNAL; PRISON; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SELF REPORT; UNITED STATES; URBAN AREA;

ADOLESCENT; ADULT; AGED; BUPRENORPHINE; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; METHADONE; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; PATIENT SELECTION; PRISONS; RECURRENCE; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57049126482     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.08.006     Document Type: Article

References (52)

1. Administrative Office of U.S. Courts. The Guide to Judiciary Policies and Procedures: Probation Manual vol. 10 (1994), Government Printing Office, Washington, DC
2. Alho H., Sinclair D., Vuori E., and Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 88 (2007) 75-78
3. Amass L., Kamien J.B., and Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend. 58 (2000) 143-152
4. Amon J.J., Garfein R.S., Ahdieh-Grant L., Armstrong G.L., Ouellet L.J., Latka M.H., Vlahov D., Strathdee S.A., Hudson S.M., Kerndt P., Des Jarlais D., and Williams I.T. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin. Infect. Dis. 46 (2008) 1852-1858
5. Anglin M.D., and Perrochet B. Drug use and crime: a historical review of research conducted by the UCLA Drug Abuse Research Center. Substance Use Misuse 33 (1998) 1871-1914
6. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts-16th International AIDS Conference epidemiology plenary. Clin. Infect. Dis. 44 (2007) 981-987
7. Binswanger I.A., Stern M.F., Deyo R.A., Heagerty P.J., Cheadle A., Elmore J.G., and Koepsell T.D. Release from prison-a high risk of death for former inmates. N. Engl. J. Med. 356 (2007) 157-165
8. Bird S.M., and Hutchinson S.J. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. Addiction 98 (2003) 185-190
9. Blansfield H.N. Inadequate treatment of opioid dependence due to society's attitudes and beliefs. Conn. Med. 60 (1996) 423-428
10. Butler T., Boonwaat L., Hailstone S., Falconer T., Lems P., Ginley T., Read V., Smith N., Levy M., Dore G., and Kaldor J. The 2004 Australian prison entrants' blood-borne virus and risk behaviour survey. Aust N Z J Public Health 31 (2007) 44-50
11. Catania, H., 2003. Public health needed in prisons. Harm Reduction News: Newsletter of the International Harm Reduction Development Program of the Open Society Institute 4, 11, 13.
12. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol TIP Series 40 (2004), Substance Abuse and Mental Health Services Administration, Rockville, MD
13. Chow S.-C., and Chang M. Adaptive Design Methods in Clinical Trials (2007), Chapman & Hall/CRC, Boca Raton, FL
14. Dolan K.A., Shearer J., MacDonald M., Mattick R.P., Hall W., and Wodak A.D. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 72 (2003) 59-65
15. Eissenberg T., Johnson R.E., Bigelow G.E., Walsh S.L., Liebson I.A., Strain E.C., et al. Controlled opioid withdrawal evaluation during 72 dose omission in buprenorphine-maintained patients. Drug Alcohol Depend. 45 (1997) 81-91
16. Fiscella K., Moore A., Engerman J., and Meldrum S. Jail management of arrestees/inmates enrolled in community methadone maintenance programs. J. Urban Health: Bull. N. Y. Acad. Med. 81 (2004) 645-654
17. Food and Drug Administration www.fda.gov/cder/ob. FDA Orange Book, accessed April 14, 2008.
18. Freudenberg N. Jails, prisons, and the health of urban populations: a review of the impact of the correctional system on community health. J. Urban Health 78 (2001) 214-235
19. Fudala P.J., Yu E., Macfadden W., Boardman C., and Chiang C.N. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 50 March (1998) 1-8
20. Garcia C.A., Correa G.C., Viver A.D., Hernandez B.S., Kinlock T.W., Gordon M.S., Avila C.A., Reyes I.C., and Schwartz R.P. Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J. Addict. Med. 1 (2007) 126-132
21. Goldsmith D.S., Hunt D.E., Lipton D.S., and Strug D.L. Methadone Folklore: Beliefs About Side Effects and Their Impact on Treatment (1984), Human Organization pp. 330-340
22. Haig T. Randomized controlled trial proves effectiveness of methadone maintenance treatment in prison. Can. HIV AIDS Policy Law Rev. 8 (2003) 48
23. Hall W., Ward J., and Matrick R. Methadone maintenance treatment in patient: the New South Wales experience. Drug Alcohol Rev. 12 (1993) 193-2003
24. Hunt D.E., Lipton D.S., Goldsmith D.S., Strug D.L., and Spunt B. It takes your heart: the image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int. J. Addict. 20 (1985) 1751-1771
25. Jasinki D.R., Pevnick J.S., and Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 35 (1978) 501-516
26. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., and Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 343 (2000) 1290-1297
27. Kang S.Y., Magura S., Nwakeze P., and Demsky S. Counselor attitudes in methadone maintenance. J. Maintenance Addict. 1 (1997) 41-58
28. Kinlock T.W., Gordon M.S., Schwartz R.P., O'Grady K., Fitzgerald T.T., and Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 91 (2007) 220-227
29. Langendam M.W., van Haastrecht H.J., van Brussel G.H., Reurs H., van den Hoek A.A., Coutinho R.A., et al. Differentiation in the Amsterdam methadone dispensing circuit: determinants of methadone dosage and site of methadone prescription. Addiction 93 (1998) 61-72
30. Lewis J.W. Buprenorphine. Drug Alcohol Depend. 14 (1985) 363-372
31. Magura S., Lee S.J., Salsitz E.A., Kolodny A., Whitley S.D., Taubes T., et al. Outcomes of buprenorphine maintenance in office-based practice. J. Addict. Dis. 26 (2007) 13-23
32. Magura S., Rosenblum A., Lewis C., and Joseph H. The effectiveness of in-jail methadone maintenance. J. Drug Issues 23 (1993) 75-99
33. McBride D.C., and McCoy C.B. The drugs-crime relationship: an analytic framework. Prison J. 73 (1993) 257-278
34. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., and Argeriou M. The fifth edition of the addiction severity index. J. Subst. Abuse. Treat. 9 (1992) 199-213
35. McMillan G.P., and Lapham S.C. Staff perspectives on methadone maintenance therapy MMT in a large southwestern jail. Addict. Res. Theory 13 (2005) 53-63
36. Michel L., and Maguet O. Guidelines for substitution treatments in prison populations [Article in French]. Encephale 31 1 Pt 1 (2005) 92-97
37. Michels I.I., Stöver H., and Gerlach R. Substitution treatment for opioid addicts in Germany. Harm Reduct J. 4 (2007) 5
38. National Association of State Alcohol and Drug Abuse Directors, Inc. Methadone Maintenance and the Criminal Justice System (2006), National Association of State Alcohol and Drug Abuse Directors, Washington, DC
39. National Institute of Justice. Drug and Alcohol Use and Related Matters among Arrestees 2003 (2004), National Institute of Justice, Washington, DC
40. National Institute on Drug Abuse. Principles of Drug Addiction Treatment (1999), National Institute on Drug Abuse, Rockville, MD
41. Perez de los Cobos J., Fidel G., Escuder G., Haro G., Sanchez N., Pascual C., et al. A satisfaction survey of opioid-dependent clients at methadone treatment centres in Spain. Drug Alcohol Depend. 73 (2004) 307-313
42. Rance M.J., and Dickens J.N. The influence of drug-receptor kinetics on the pharmacological and pharmaco-kinetic profiles of buprenorphine. In: Van Ree J.M., and Premiums L. (Eds). Characteristics and Functions of Opioids (1978), Elsevier/North-Holland Biomedical Press, Amsterdam
43. Reynaud-Maurupt C., Caer Y., Escaffre N., Gagneau M., Galinier A., Marzo J.N., and Meroueh F. High-dose buprenorphine substitution during incarceration. Presse Med. 34 (2005) 487-490. French
44. Rosenblum A., Magura S., and Joseph H. Ambivalence toward methadone treatment among intravenous drug users. J. Psychoactive Drugs 23 (1991) 21-27
45. Simpson D.D., and Knight K. Health, addiction treatment, and the criminal justice system. Report to Physician Leadership on National Drug Policy (1998), Brown University Center for Alcohol and Addiction Studies, Providence, RI
46. Stallwitz A., and Stöver H. The impact of substitution treatment in prisons-a literature review. Int. J. Drug Policy 186 (2007) 464-474
47. Tomasino V., Swanson A.J., Nolan J., and Shuman H. The Key Extended Entry Program KEEP: a methadone treatment program for opiate-dependent inmates. Mt. Sinai J. Med. 68 (2001) 14-20
48. Walsh S.L., Preston K.L., Bigelow G.E., and Stitzer M.L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274 (1995) 361-372
49. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., and Bigelow G.E. Clinical pharmacology buprenorphine: ceiling affects at high dose. Clin. Pharmacol. Ther. 55 (1994) 569-580
50. Westermeyer J. Addiction, community and state: a review. Am. J. Addict. 91 (2000) 79-87
51. White H.R., and Gorman D.M. Dynamics of the drug-crime relationship. In: Jefferis E., and Munsterman J. (Eds). Crime and Justice 2000, Vol. 1: The Nature of Crime: Continuity and Change (2000), National Institute of Justice, Washington, DC 151-218
52. Zule W.A., and Desmond D.P. Attitudes toward methadone maintenance: implications for HIV prevention. J. Psychoactive Drugs 301 (1998) 89-97